Development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib
We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase inhibitors. Sec...
Main Authors: | David Sanford, Maria MacDonald, Michael Nicolle, Anargyros Xenocostas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-06-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | http://www.pagepress.org/journals/index.php/hr/article/view/5288 |
Similar Items
-
Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
by: Khaleed J Khaleel, et al.
Published: (2018-01-01) -
Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report
by: Meng Xiao, et al.
Published: (2017-12-01) -
Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
by: Massimo Breccia, et al.
Published: (2017-10-01) -
Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients
by: Zaidi U, et al.
Published: (2019-02-01) -
Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
by: Prahathishree Mohanavelu, et al.
Published: (2021-04-01)